A client with end-stage renal disease (ESRD) is experiencing severe fatigue, weakness, and decreased urine output. Laboratory tests show elevated levels of blood urea nitrogen (BUN) and creatinine. Which of the following is the primary indication for initiating dialysis in this client?

A) This statement is incorrect. Hyperkalemia (elevated potassium levels) can be a concern in ESRD, but it is not the primary indication described in the scenario. While hyperkalemia may occur in ESRD, the primary concern leading to the need for dialysis is the uremia and its associated symptoms.

B) This statement is incorrect. Hypophosphatemia (low phosphorus levels) can be a concern in ESRD, but it is not the primary indication for initiating dialysis in this case. Uremia and its associated symptoms are the primary concerns leading to the need for dialysis.

C) Uremia, which is characterized by elevated levels of urea and other waste products in the blood, is a critical indication for initiating dialysis in clients with end-stage renal disease. Dialysis helps remove these toxic substances from the bloodstream and may alleviate symptoms like fatigue, weakness, and decreased urine output.

D) This statement is incorrect. Hyponatremia (low sodium levels) is not the primary indication for initiating dialysis in this scenario. Uremia and the accumulation of waste products are the primary concerns that require dialysis to address.

QUESTIONS

A) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) are not used to prevent infections during dialysis. They are used to address anemia by stimulating red blood cell production.

B) This statement is accurate. Erythropoietin-stimulating agents (ESAs) stimulate the bone marrow to produce more red blood cells, addressing anemia commonly associated with chronic kidney disease and dialysis.

C) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) do not reduce the risk of blood clot formation. They are specific to stimulating the production of red blood cells.

D) This statement is incorrect. Erythropoietin-stimulating agents (ESAs) do not enhance kidney function and filtration. They target the production of red blood cells to address anemia associated with ESRD and dialysis.